


For the Treatment of Superficial Femoral Artery (SFA) or Iliac Lesions

When Trust Is Put in You, Put Yours in What's Been Proven.

FEATURING RESULTS OF THE STROLL* STUDY






Contents

STENT 3
Design 4
Stability 5
Radial Force 6
Fracture Rate 7
COMPETITORS 8
OUTCOMES 9
STROLL Study
Clinical
Patient
7 ducine :
ORDERING INFORMATION13
S.M.A.R.T. CONTROL™ and
S.M.A.R.T.™ Vascular Stent Systems
THE CORDIS™ COMMITMENT

STENT

Design
Stability
Radial Force
Engineering

Engineered to Perform



Optimizing Outcomes through Unique Stent Design

Scaffolding

Smaller cell size and uniform coverage can help prevent vessel prolapse.¹

Longitudinal stability


Greater stability minimizes stretching at deployment, thereby increasing placement accuracy.¹

Radial force

The stent's ability to resist compression maintains luminal gain.¹

Delivering Superior Stability by Design

Up to 300% greater stability for accurate placement with the S.M.A.R.T.™ Vascular Stent Systems.




A foundation built on uniform scaffolding and small cell size.




Built With Unmatched Radial Force

Up to 118% greater radial force than other nitinol stents with the S.M.A.R.T.™ Vascular Stent Systems.




Designed to Maintain Luminal Gain




S.M.A.R.T.™ Vascular Stent Systems are designed to **maintain luminal gain.**

Lower Fracture Rate. Higher Satisfaction.

S.M.A.R.T.™ Vascular Stent Systems have a low fracture rate maintained out to 3 years in the STROLL Study.



The Stent Fracture Grading Scale




Stent strut fractures are commonly categorized into five types.

Type I Type V Type II Type III Type IV One strut Multiple strut Complete Complete transverse Complete fracture fractures transverse linear linear fracture with transaxial fracture displacement fracture


Adapted from Rocha-Singh et al 2

Fracture Rates With Other Stents

In clinical trials, severe fractures were observed in two of our competitors.



LifeStent[™] Stent (RESILIENT Trial—all phases and arms) at 18 months²



^{2.} The RESILIENT Randomized Trial: Three-Year Results, Resiliant LINC Presentation 2013. The third-party trademarks used herein are trademarks of their respective owners.

OUTCOMES

STROLL Study
Clinical Outcomes
Patient Outcomes

When Trust Is Put in You, Put Yours in What's Been Proven.

Conducted over 3 years, the STROLL* Study proved that S.M.A.R.T.™ Vascular Stent Systems provided effective SFA revascularization.¹

Clinical Outcomes	1 year	2 years	3 years
Primary patency [‡]	81.7%	74.9%	72.7%
Freedom from TLR	87.6%	80.3%	78.5%
Stent fracture rate	2% (all Type I)	2% (all Type I)	3.6% (all Type I)
Patient Outcomes	1 year	2 years	3 years
Patients with minimal or no PAD symptoms [§]	76.6%	81.8%	77.8%
Patients with normal ABI (>0.8)	81.0%	80.7%	76.5%

Quality-of-Life (QoL) Outcomes

As reported by patients, the overall health-related QoL benefit was very large and sustained out to 3 years.

- 10-15 years of age on generic measures
- ~4x the Minimum Clinically Importance Difference (MCID) on PAD specific scales


^{*} The S.M.A.R.T.™ Nitinol Self-expanding Stent in the Treatment of Obstructive Superficial Femoral Artery Disease (STROLL) study.

[†] A principal investigator of the STROLL study. ‡ Defined as no significant reduction in flow detectable by duplex ultrasound and no further clinically driven target lesion revascularization.


[§] Defined as Rutherford-Becker classification 0 or 1.

The Stent With the Difference Makers

High primary patency rate maintained out to 3 years in the STROLL Study with the $S.M.A.R.T.^{TM}$ Vascular Stent Systems¹.




Strong rate of freedom from TLR maintained out to 3 years in the STROLL study¹.




Providing Critical Patient Outcomes

Minimal or no signs of PAD* in 3 of 4 patients maintained out to 3 years in the STROLL Study as measured using Rutherford-Becker classification¹.



Improvement in ABI was sustained out to 3 years.



Normal ABI in over 3 out of 4 patients out to 3 years when treated with the S.M.A.R.T.™ Vascular Stent.

81.0%, 80.7% and 76.5% of patients had ABI >0.8 at one, two and three years, respectively, after deployment of S.M.A.R.T.™ Vascular Stent Systems.

ORDERING INFORMATION

S.M.A.R.T. CONTROL[™] and S.M.A.R.T. [™] Vascular Stent Systems

Product Description					
Туре	MicroMesh Geometry, Segmented Design	Sheath Compatibility	6F (6-10mm) & 7F (12-14mm)		
Material	Nitinol, with MicroMarker Technology	Guide Catheter			
Maximum Guidewire	0.035"	Compatibility	8F (6-10mm) & 9F (12-14mm)		
Stent Lengths	20 - 150mm	Stent Diameters	6-14mm (Stent diameter should be 1-2mm greater than vessel diameter)		
Stent Delivery Systems	Delivery Handle: 20-100mm Stent lengths. Pin and Pull: 120 and 150mm Stent Lengths	Stent Delivery System Working Lengths	80cm (S suffix) & 120cm (M suffix)		

S.M.A.R.T. CONTROL[™] and S.M.A.R.T. Stent .035" Guidewire Compatibility

Stent Diameter x Stent	Unconstrained Stent Diameter	Unconstrained Stent Length	Min/Max Vessel Diameter	Catalogue Number Length of Delivery System (cm)	
	(mm)	(mm) (mm)		80 cm	120 cm
6 x 20	6	20	4 - 5	C06020SV	
6 x 30	6	30	4 - 5	C06030SV	C06030MV
6 x 40	6	40	4 - 5	C06040SV	C06040MV
6 x 60	6	60	4 - 5	C06060SL	C06060MV
6 x 80	6	80	4 - 5	C06080SV	C06080MV
6 x 100	6	100	4 - 5	C06100SV	C06100MV
7 x20	7	20	5 - 6	C07020SV	
7 x 30	7	30	5 - 6	C07030SV	C07030MV
7 x 40	7	40	5 - 6	C07040SV	C07040MV
7 x 60	7	60	5 - 6	C07060SV	C07060MV
7 x 80	7	80	5 - 6	C07080SV	C07080MV
7 x 100	7	100	5 - 6	C07100SV	C07100MV
8 x 20	8	20	6 - 7	C08020SV	
8 x 30	8	30	6 - 7	C08030SV	C08030MV
8 x 40	8	40	6 - 7	C08040SV	C08040MV
8 x 60	8	60	6 - 7	C08060SV	C08060MV
8 x 80	8	80	6 - 7	C08080SV	C08080MV
8 x 100	8	100	6 - 7	C08100SV	C08100MV
9 x 20	9	20	7 - 8	C09020SV	
9 x 30	9	30	7 - 8	C09030SV	C09030MV
9 x 40	9	40	7 - 8	C09040SV	C09040MV
9 x 60	9	60	7 - 8	C09060SV	C09060MV
9 x 80	9	80	7 - 8	C09080SV	C09080MV
10 x 20	10	20	8 - 9	C10020SL	
10 x 30	10	30	8 - 9	C10030SL	C10030MV
10 x 40	10	40	8 - 9	C10040SL	C10040MV
10 x 60	10	60	8 - 9	C10060SL	C10060MV
10 x 80	10	80	8 - 9	C10080SL	C10080MV

Long S.M.A.R.T.™.035" Stent 120mm and 150mm Stents

Stent Configuration Stent Diameter x Length (mm)	Unconstrained Stent Diameter (mm)	Expanded Stent Length (mm)	Min/Max Vessel Diameter	Catalog Number Length of Delivery System (cm)	
			(mm)	80	120
6 x 120	6	120	4 - 5	C06120SV	C06120MV
7 x 120	7	120	5 - 6	C07120SV	C07120MV
8 x 120	8	120	5 - 6	C08120SV	C08120MV
6 x 150	6	150	4 - 5	C06150SV	C06150MV
7 x 150	7	150	5 - 6	C07150SV	C07150MV
8 x 150	8	150	5 - 6	C08150SV	C08150MV

S.M.A.R.T. CONTROL™ Large 12 x 14 mm Stent Delivery System

Stent Configuration Stent Diameter x Length (mm)	Unconstrained Stent Diameter (mm)	Unconstrained Stent Length (mm)	Min/Max Vessel Diameter	Catalogue Number Length of Delivery System (cm)	
			(mm)	80 cm	120 cm
12 x 30	12	30	10 - 11	C12030SV	C12030MV
12 x 40	12	40	10 - 11	C12040SV	C12040MV
12 x 60	12	60	10 - 11	C12060SL	C12060MV
12 x 80	12	80	10 - 11	C12080SV	C12080MV
14 x 30	14	30	12 - 13	C14030SV	C14030MV
14 x 40	14	40	12 - 13	C14040SV	C14040MV
14 x 60	14	60	12 - 13	C14060SV	C14060MV
14 x 80	14	80	12 - 13	C14080SV	C14080MV

The Cordis Commitment

Cordis is committed to providing world-class customer support and sponsoring extensive training programs for thousands of physicians each year across the globe.

Cordis provides a comprehensive portfolio of Lower Extremity Solutions that helps simplify even your most difficult procedures. By sponsoring extensive educational programs and offering a broad range of access, crossing, and interventional products, we are living our commitment—partnering with you to improve clinical and patient outcomes. For more information, please contact your local Cordis sales representative.

For Healthcare Professionals Only.

Important information: Prior to use, refer to the instructions for use supplied with this device for indications, contraindications, side effects, suggested procedure, warnings and precautions. As part of its continuous product development policy, Cordis reserves the right to change product specifications without prior notification.

 ${\it Please contact your Cord is representative for additional product availability information.}$

CORDIS, Cordis LOGO, S.M.A.R.T. and S.M.A.R.T. CONTROL are trademarks of Cordis and may be registered in the US and/or in other countries. All other marks are the property of their respective owners.

